Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of SPY072 in Rheumatic Disease
NCT07148414 · View on ClinicalTrials.gov ↗
Study Summary
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SPY002-072
Study Locations (20)
California
- Site 114 — Chula Vista
- Site 111 — Covina
- Site 108 — Tujunga
- Site 112 — Upland
- Site 107 — Whittier
Florida
- Site 109 — Hialeah
- Site 106 — Ormond Beach
- Site 110 — Tampa
Texas
- Site 105 — Corpus Christi
- Site 103 — Tomball
- Site 102 — Tomball
Plovdiv
- Site 506 — Plovdiv
- Site 505 — Plovdiv
Arizona
- Site 113 — Avondale
Pennsylvania
- Site 104 — Duncansville
Lovech
- Site 503 — Lovech
Pleven
- Site 502 — Pleven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148414
The ClinicalTrials.gov registry entry for NCT07148414 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spyre Therapeutics, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 8 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07148414 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07148414 about?
NCT07148414 is a clinical study titled "A Study of SPY072 in Rheumatic Disease". This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
What is the current status of trial NCT07148414?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2025-08-21. Estimated completion is 2028-03-31.
What conditions does trial NCT07148414 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatic Diseases, Axial Spondyloarthritis, Rheumatologic Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07148414?
The interventions under investigation include: Placebo (DRUG), SPY002-072 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07148414?
This trial is sponsored by Spyre Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07148414 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.